ConCallIQ
Go Pro
TCS Information Technology 09 Jan 2025

Tata Consultancy Services Ltd — Q3 FY25

TCS reported Q3 FY25 revenue of INR 63,973 crore, up 5.6% YoY, with operating margin expanding 40 bps sequentially to 24.5%.

bullish high
Compare with...
Revenue ₹63,973 Cr +5.6%
EBITDA
EBITDA Margin 24.5% +40bps
Duration
Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

TCS reported Q3 FY25 revenue of INR 63,973 crore, up 5.6% YoY, with operating margin expanding 40 bps sequentially to 24.5%. The highlight was a record TCV of $10.2 billion, broad-based across industries and geographies, with BFSI contributing $3.2 billion. Management noted early signs of discretionary spending revival, particularly in BFSI and retail, and a shortening of deal cycles. AI/GenAI deal momentum continues, with agentic AI gaining traction. However, North America revenue declined 2.3% YoY, and headcount fell to 607,354. The BSNL contract is 70% complete and will taper from Q4. Management expects CY25 to be better than CY24, driven by improving demand and strong pipeline. Key risk: macro uncertainty from US trade policies could dampen discretionary recovery.

Bear Cases3 alive · 0 deadPromises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace

Focused Modules

Bear Cases 4 tracked

Bear Cases vs Reality

Revenue growth remains muted despite record TCV Alive 3, weakening 1, dead 0.

View Bear Cases →
Promises 3 promises

Promise Tracker

0 delivered, 0 close, 3 missed.

View Promises →
!Risks 4 risks

Risk Intelligence

Macro uncertainty from US trade policies

View Risks →
Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Total Contract Value (TCV) $10.2B
+double-digit YoY

Record quarterly TCV, broad-based across industries and geographies, with no mega deals.

BFSI TCV $3.2B
strong YoY

BFSI led TCV with $3.2 billion; all large BFSI accounts in North America contributed to growth.

Attrition (LTM) 13%
flat sequentially

Attrition stable at 13%; workforce at 607,354 with 35.3% women.

Deal Cycle (deals >$20M) reduced by a few weeks
improved vs prior quarter

Deal cycle shortened for large deals, indicating faster decision-making by clients.

What Changed vs Last Quarter

Comparing Q3 FY25 vs Q2 FY25
3 new guidance3 dropped3 new risk3 risk resolved
NEW
BSNL revenue to taper from Q4 FY25 through Q2 FY26

The BSNL contract is 70% complete; revenue will start tapering in Q4 and may extend to Q2 FY26. Management expects to replace most of it via other opportunities.

NEW
CY25 to be better than CY24 for international business

Management expects stronger growth in CY25 vs CY24, driven by early discretionary recovery and strong deal pipeline, despite BSNL headwinds.

NEW
Increased campus hiring next year

Preparations underway to onboard a higher number of campus hires next fiscal year, signaling confidence in future demand.

UPDATED
Margin aspiration of 26% by Q4 FY25

Management aims to exit Q4 at 26% operating margin, within the 26%-28% aspirational band, driven by operating efficiencies and BSNL tapering.

DROPPED
Life sciences headwinds to stabilize in Q3, return to growth in Q4

Client-specific headwinds in life sciences and healthcare are expected to stabilize in Q3 and return to growth in Q4.

DROPPED
BSNL deal peak revenue to continue for one more quarter, then taper

The BSNL transformational program is at peak revenue; expected to remain at similar levels for one more quarter before tapering.

DROPPED
Growth markets as long-term growth driver

TCS is investing significantly in India, APAC, Latin America, and Middle East & Africa as sustainable long-term growth drivers.

NEW RISK
Macro uncertainty from US trade policies

Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.

NEW RISK
North America revenue decline

North America revenue declined 2.3% YoY, and TTH slowed considerably in the US due to market-specific issues and strained client profitability.

NEW RISK
Life sciences and healthcare recovery uncertainty

Life sciences healthcare declined 4.3% YoY; recovery depends on policy clarity in the US, which is uncertain.

RISK GONE
Client-specific scope reductions in life sciences

A large life sciences client abruptly reduced scope, causing revenue decline. Recovery depends on client's future investment decisions.

RISK GONE
Prolonged weakness in telecom and manufacturing

Telecom and manufacturing verticals face structural headwinds; telecom due to CapEx caution, manufacturing due to labor and supply chain issues.

RISK GONE
Margin pressure from growth market investments

Growth markets have lower margins; scaling them may pressure overall margins until volumes improve.

🤫 Topics management stopped discussing

Fresher hiring of 40,000 for FY24 still on track

Mentioned in Q1 FY24, Q1 FY25, Q3 FY24

CHRO Milind Lakkad indicated that the company aims to hire close to 40,000 trainees in FY25, consistent with historical practice.

Prolonged demand softness in North America and BFSI

Mentioned in Q1 FY24, Q1 FY25, Q3 FY24

North America revenue declined 1.1% YoY and BFSI remained negative YoY, with management citing ongoing client uncertainty and delayed decision-making.

FY25 growth expected to be better than FY24

Mentioned in Q1 FY25, Q4 FY24

Management reiterated that FY25 will be better than FY24 in terms of revenue growth, but declined to provide specific numbers.

Headcount decline may signal demand softness

Mentioned in Q2 FY24, Q3 FY24

Headcount declined by 5,600 in Q3. CHRO said further decline would not be surprising, which could signal lower utilization or demand.

Operating margin aspirational band of 26-28%

Mentioned in Q1 FY24, Q1 FY25

CFO Samir Seksaria reaffirmed commitment to the 26-28% operating margin band, with levers including productivity, utilization, and pricing.

Fast read

Guidance and risk preview

Top guidance Margin aspiration of 26% by Q4 FY25

Management aims to exit Q4 at 26% operating margin, within the 26%-28% aspirational band, driven by operating efficiencies and BSNL tapering.

Top risk Macro uncertainty from US trade policies

Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.

View Risks →